Mohit Bansal
Stock Analyst at Wells Fargo
(4.35)
# 345
Out of 5,072 analysts
178
Total ratings
69.23%
Success rate
9.81%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Overweight | $90 → $125 | $105.66 | +18.30% | 12 | Nov 24, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $615 → $700 | $787.32 | -11.09% | 20 | Nov 20, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $170 → $235 | $180.05 | +30.52% | 3 | Nov 18, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $1 → $3 | $3.13 | -4.15% | 5 | Nov 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Overweight | $50 → $55 | $42.20 | +30.33% | 3 | Nov 11, 2025 | |
| AMGN Amgen | Maintains: Overweight | $280 → $300 | $341.11 | -12.05% | 11 | Nov 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $140 → $145 | $127.12 | +14.07% | 12 | Oct 31, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $90 → $70 | $56.29 | +24.36% | 6 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $240 → $260 | $231.80 | +12.17% | 10 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $27 → $35 | $36.01 | -2.80% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4 | $2.47 | +61.94% | 1 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $460 | $429.82 | +7.02% | 11 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $99.71 | +50.44% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $43.94 | +6.96% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $65 | $72.82 | -10.74% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $53 | $49.05 | +8.05% | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $970 → $1,100 | $1,109.94 | -0.90% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $181.96 | -23.06% | 14 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $17.64 | +70.07% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $29.43 | +137.85% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.72 | +16.64% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $143.53 | +18.44% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $19.99 | +9,279.69% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.01 | +1,691.04% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $11.85 | +60.34% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.11 | +5,305.41% | 4 | Dec 3, 2019 |
Merck & Co.
Nov 24, 2025
Upgrades: Overweight
Price Target: $90 → $125
Current: $105.66
Upside: +18.30%
Regeneron Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $615 → $700
Current: $787.32
Upside: -11.09%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $170 → $235
Current: $180.05
Upside: +30.52%
Ironwood Pharmaceuticals
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $1 → $3
Current: $3.13
Upside: -4.15%
Mineralys Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $42.20
Upside: +30.33%
Amgen
Nov 5, 2025
Maintains: Overweight
Price Target: $280 → $300
Current: $341.11
Upside: -12.05%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $140 → $145
Current: $127.12
Upside: +14.07%
BioMarin Pharmaceutical
Oct 28, 2025
Maintains: Overweight
Price Target: $90 → $70
Current: $56.29
Upside: +24.36%
AbbVie
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $231.80
Upside: +12.17%
Travere Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $36.01
Upside: -2.80%
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $2.47
Upside: +61.94%
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $429.82
Upside: +7.02%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $99.71
Upside: +50.44%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $43.94
Upside: +6.96%
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $72.82
Upside: -10.74%
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $49.05
Upside: +8.05%
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $1,109.94
Upside: -0.90%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $181.96
Upside: -23.06%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $17.64
Upside: +70.07%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $29.43
Upside: +137.85%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.72
Upside: +16.64%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $143.53
Upside: +18.44%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $19.99
Upside: +9,279.69%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $2.01
Upside: +1,691.04%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $11.85
Upside: +60.34%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.11
Upside: +5,305.41%